ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB428

Study of Pulmonary Hypertension in Patients with CKD in a Teaching Hospital

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical

Author

  • Gorrepati, Geetika, Tulane University, New Orleans, Louisiana, United States
Background

Pulmonary hypertension is defined as a mean artery pressure >25 mm Hg and
is a serious and progressive complication of chronic kidney disease and end-stage renal
disease. Identifying pulmonary arterial hypertension (PAH) can be challenging but is
important in this population since management strategizes differ from those for patients with
ESKD who donot have PH.

Methods

This was an observational cross section study conducted on 85 patients
of CKD stage 4 and 5 (based on KDIGO 2012 criteria) admitted to the medicine wards in
Mamata academy of medical sciences, bachupally Hyderabad from the year 2022-2023

Results

In our study 35.2 % cases showed no PAH .Mild PAH noted in 23.5% cases ,
Moderate PAH noted in 36.4% cases and 4.7% showed severe PAH . systolic and diastolic
blood pressure with PH showed significant association .Presence of haemodialysis
significantly associated with PH. Significant association was seen with age and BMI. Low
haemoglobin was also significantly associated with PH.

Conclusion

CKD patients have a higher prevalence of pulmonary hypertension. The
prevalence of pulmonary hypertension is high in stage 5 CKD patients, and it is also higher in
dialysis patients.

Funding

  • Private Foundation Support